Clement L Ren1, Rebecca L Morgan2, Christopher Oermann3, Helaine E Resnick4, Cynthia Brady5, Annette Campbell6, Richard DeNagel7, Margaret Guill8, Jeffrey Hoag9, Andrew Lipton10, Thomas Newton11, Stacy Peters12, Donna Beth Willey-Courand13, Edward T Naureckas14. 1. 1 Indiana University School of Medicine, Indianapolis, Indiana. 2. 2 McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada. 3. 3 Children's Mercy-Kansas City, Kansas City, Missouri. 4. 4 Resnick, Chodorow, and Associates, Silver Spring, Maryland. 5. 5 Children's Hospitals and Clinics of Minnesota, Saint Paul, Minnesota. 6. 6 Kansas City University of Medicine and Biosciences, Kansas City, Missouri. 7. 7 Patient Community Advisor, New York, New York. 8. 8 Dartmouth College Geisel School of Medicine, Hanover, New Hampshire. 9. 9 Drexel University College of Medicine, Philadelphia, Pennsylvania. 10. 10 Walter Reed National Military Medical Center, Bethesda, Maryland. 11. 11 Miller Children's and Women's Hospital Long Beach, Long Beach, California. 12. 12 South Dakota State University, College of Pharmacy, Brookings, South Dakota. 13. 13 University of Texas Health Science Center at San Antonio, San Antonio, Texas; and. 14. 14 University of Chicago, Chicago, Illinois.
Abstract
RATIONALE: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators are a new class of medications targeting the underlying defect in CF. Ivacaftor (IVA) and IVA combined with lumacaftor (LUM; IVA/LUM) have been approved by the U.S. Food and Drug Administration (FDA) for use in patients with CF. However, the FDA label for these medications encompasses patient groups that were not studied as part of the drug approval process. CF clinicians, patients, and their families have recognized a need for recommendations to guide the use of these medications. OBJECTIVE: Develop evidence-based guidelines for CFTR modulator therapy in patients with CF. METHODS: A multidisciplinary committee of CF caregivers and patient representatives was assembled. A methodologist, an epidemiologist, a medical librarian, and a biostatistician were recruited to assist with the literature search, evidence grading, and generation of recommendations. The committee developed clinical questions using the Patient-Intervention-Comparison-Outcome format. A systematic review was conducted to find relevant publications. The evidence was then evaluated using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach, and recommendations were made based on this analysis. RESULTS: For adults and children aged 6 years and older with CF due to gating mutations other than G551D or R117H, the guideline panel made a conditional recommendation for treatment with IVA. For those with the R117H mutation, the guideline panel made a conditional recommendation for treatment with IVA for 1) adults aged 18 years or older, and 2) children aged 6-17 years with a forced expiratory volume in 1 second (FEV1) less than 90% predicted. For those with the R117H mutation, the guideline panel made a conditional recommendation against treatment with IVA for 1) children aged 12-17 years with an FEV1 greater than 90% predicted, and 2) children less than 6 years of age. Among those with two copies of F508del, the guideline panel made a strong recommendation for treatment with IVA/LUM for adults and children aged 12 years and older with an FEV1 less than 90% predicted; and made a conditional recommendation for treatment with IVA/LUM for 1) adults and children aged 12 years or older with an FEV1 greater than 90% predicted, and 2) children aged 6-11 years. CONCLUSIONS: Using the GRADE approach, we have made recommendations for the use of CFTR modulators in patients with CF. These recommendations will be of help to CF clinicians, patients, and their families in guiding decisions regarding use of these medications.
RATIONALE: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators are a new class of medications targeting the underlying defect in CF. Ivacaftor (IVA) and IVA combined with lumacaftor (LUM; IVA/LUM) have been approved by the U.S. Food and Drug Administration (FDA) for use in patients with CF. However, the FDA label for these medications encompasses patient groups that were not studied as part of the drug approval process. CF clinicians, patients, and their families have recognized a need for recommendations to guide the use of these medications. OBJECTIVE: Develop evidence-based guidelines for CFTR modulator therapy in patients with CF. METHODS: A multidisciplinary committee of CF caregivers and patient representatives was assembled. A methodologist, an epidemiologist, a medical librarian, and a biostatistician were recruited to assist with the literature search, evidence grading, and generation of recommendations. The committee developed clinical questions using the Patient-Intervention-Comparison-Outcome format. A systematic review was conducted to find relevant publications. The evidence was then evaluated using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach, and recommendations were made based on this analysis. RESULTS: For adults and children aged 6 years and older with CF due to gating mutations other than G551D or R117H, the guideline panel made a conditional recommendation for treatment with IVA. For those with the R117H mutation, the guideline panel made a conditional recommendation for treatment with IVA for 1) adults aged 18 years or older, and 2) children aged 6-17 years with a forced expiratory volume in 1 second (FEV1) less than 90% predicted. For those with the R117H mutation, the guideline panel made a conditional recommendation against treatment with IVA for 1) children aged 12-17 years with an FEV1 greater than 90% predicted, and 2) children less than 6 years of age. Among those with two copies of F508del, the guideline panel made a strong recommendation for treatment with IVA/LUM for adults and children aged 12 years and older with an FEV1 less than 90% predicted; and made a conditional recommendation for treatment with IVA/LUM for 1) adults and children aged 12 years or older with an FEV1 greater than 90% predicted, and 2) children aged 6-11 years. CONCLUSIONS: Using the GRADE approach, we have made recommendations for the use of CFTR modulators in patients with CF. These recommendations will be of help to CF clinicians, patients, and their families in guiding decisions regarding use of these medications.
Entities:
Keywords:
Clinical Practice Guidelines; Development; Grading of Recommendations Assessment; and Evaluation; ivacaftor; lumacaftor
Authors: Jane C Davies; Samuel M Moskowitz; Cynthia Brown; Alexander Horsley; Marcus A Mall; Edward F McKone; Barry J Plant; Dario Prais; Bonnie W Ramsey; Jennifer L Taylor-Cousar; Elizabeth Tullis; Ahmet Uluer; Charlotte M McKee; Sarah Robertson; Rebecca A Shilling; Christopher Simard; Fredrick Van Goor; David Waltz; Fengjuan Xuan; Tim Young; Steven M Rowe Journal: N Engl J Med Date: 2018-10-18 Impact factor: 91.245
Authors: Ana M Matos; Andreia Gomes-Duarte; Márcia Faria; Patrícia Barros; Peter Jordan; Margarida D Amaral; Paulo Matos Journal: Sci Rep Date: 2018-08-29 Impact factor: 4.379
Authors: Alice C Eastman; Rhonda G Pace; Hong Dang; Melis Atalar Aksit; Briana Vecchio-Pagán; Anh-Thu N Lam; Wanda K O'Neal; Scott M Blackman; Michael R Knowles; Garry R Cutting Journal: J Cyst Fibros Date: 2021-03-02 Impact factor: 5.527